CDC7 and neoplasm: Several studies have reported that inhibition of CDC7 exhibits potent anti‐tumor activity and promotes drug sensitivity through multiple mechanisms in preclinical models,[51, 52, 53] some of which have progressed into clinical trials for cancer treatments.[54] Further knockdown of CDC7 in resistant cells synergized with PARPi.